ArticleScience translational medicine2018
Afatinib restrains K-RAS-driven lung tumorigenesis.
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers.
0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed
13.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 126 citations in OpenAlex.
- A Roadmap to Transform Lung Cancer Outcomes: Priorities in Biology, Therapeutic Innovation, Early Detection, Prevention, and Interception.Cancer discovery · 2026Review
- KRAS mutated lung adenocarcinoma responds to pan-ERBB and Aurora kinase inhibitors.NPJ precision oncology · 2026Article
- Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges.Signal transduction and targeted therapy · 2025Review
- A feedforward loop between STAT1 and YAP1 stimulates lipid biosynthesis, accelerates tumor growth, and promotes chemotherapy resistance in mutant KRAS colorectal cancer.Communications biology · 2025Article
- Molecular insights into immune evasion and therapeutic paradigms in pancreatic cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- EGFR controls transcriptional and metabolic rewiring in KRASEMBO molecular medicine · 2025Article
- BRAFbioRxiv : the preprint server for biology · 2025Article
- Blood-based biomarkers in pancreatic ductal adenocarcinoma: developments over the last decade and what holds for the future- a review.Frontiers in oncology · 2025Review
- Tumor-associated macrophages drive heterogenetic CD10International journal of biological sciences · 2025Article
- Therapeutic strategies for KRAS G12C-mutant non-small cell lung cancer: from bench to bedside and beyond.Frontiers in pharmacology · 2025Review
- Leveraging CAR macrophages targeting c-Met for precision immunotherapy in pancreatic cancer: insights from single-cell multi-omics.Molecular medicine (Cambridge, Mass.) · 2024Article
- Pneumonic-type lung adenocarcinoma with KRAS G12V mutation and sustained response to Afatinib.Pneumonia (Nathan Qld.) · 2024Article
- Kinase signalling adaptation supports dysfunctional mitochondria in disease.Frontiers in molecular biosciences · 2024Review
- D-mannose induces TFE3-dependent lysosomal degradation of EGFR and inhibits the progression of NSCLC.Oncogene · 2023Article
- A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation.Cancer chemotherapy and pharmacology · 2023Article
- Novel strategy for oncogenic alteration-induced lipid metabolism reprogramming in pancreatic cancer.Acta biochimica et biophysica Sinica · 2023Review
- Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development-a narrative review.Translational lung cancer research · 2023Review
- Review
- Targeting RAS mutants in malignancies: successes, failures, and reasons for hope.Cancer communications (London, England) · 2023Review
- Drug Repurposing against KRAS Mutant G12C: A Machine Learning, Molecular Docking, and Molecular Dynamics Study.International journal of molecular sciences · 2022Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
25 authors at 8 institutions in 4 countries.
Herwig P MollDepartment of Physiology, Center of Physiology and Pharmacology and Comprehensive Cancer Center (CCC), Medical University of Vienna, AT-1090 Vienna, Austria.ORCID 0000-0001-6438-9068
Klemens PranzLudwig Boltzmann Institute for Cancer Research, AT-1090 Vienna, Austria.ORCID 0000-0003-2086-5725
Monica MusteanuSpanish National Cancer Research Centre, E-28029 Madrid, Spain.ORCID 0000-0002-1753-3765
Beatrice GrabnerLudwig Boltzmann Institute for Cancer Research, AT-1090 Vienna, Austria.
Natascha HruschkaLudwig Boltzmann Institute for Cancer Research, AT-1090 Vienna, Austria.
Julian MohrherrLudwig Boltzmann Institute for Cancer Research, AT-1090 Vienna, Austria.
Petra AignerLudwig Boltzmann Institute for Cancer Research, AT-1090 Vienna, Austria.
Patricia StiedlLudwig Boltzmann Institute for Cancer Research, AT-1090 Vienna, Austria.
Luka BrcicInstitute of Pathology, Medical University of Graz, AT-8036 Graz, Austria.ORCID 0000-0002-9098-8416
Viktoria LaszloDivision of Thoracic Surgery, Department of Surgery and CCC, Medical University of Vienna, AT-1090 Vienna, Austria.ORCID 0000-0002-6567-3965
Daniel SchramekInstitute of Molecular Biotechnology of the Austrian Academy of Sciences, AT-1030 Vienna, Austria.
Richard MorigglLudwig Boltzmann Institute for Cancer Research, AT-1090 Vienna, Austria.ORCID 0000-0003-0918-9463
Robert EferlInstitute of Cancer Research, Medical University of Vienna and CCC, AT-1090 Vienna, Austria.ORCID 0000-0002-6074-7144
Judit MoldvayDepartment of Tumor Biology, National Korányi Institute of Pulmonology, Semmelweis University, HU-1122 Budapest, Hungary.
Katalin DezsoFirst Department of Pathology and Experimental Cancer Research, Semmelweis University, HU-1122 Budapest, Hungary.
Pedro P Lopez-CasasSpanish National Cancer Research Centre, E-28029 Madrid, Spain.ORCID 0000-0001-9866-7361
Dagmar StoiberLudwig Boltzmann Institute for Cancer Research, AT-1090 Vienna, Austria.ORCID 0000-0002-8824-0767
Manuel HidalgoSpanish National Cancer Research Centre, E-28029 Madrid, Spain.
Josef PenningerInstitute of Molecular Biotechnology of the Austrian Academy of Sciences, AT-1030 Vienna, Austria.ORCID 0000-0002-8194-3777
Maria SibiliaInstitute of Cancer Research, Medical University of Vienna and CCC, AT-1090 Vienna, Austria.
Balázs GyőrffyMTA TK Lendület Cancer Biomarker Research Group, Institute of Enzymology and Second Department of Pediatrics, Semmelweis University, HU-1122 Budapest, Hungary.
Mariano BarbacidSpanish National Cancer Research Centre, E-28029 Madrid, Spain.
Balázs DomeDivision of Thoracic Surgery, Department of Surgery and CCC, Medical University of Vienna, AT-1090 Vienna, Austria.ORCID 0000-0001-8799-8624
Helmut PopperInstitute of Pathology, Medical University of Graz, AT-8036 Graz, Austria.ORCID 0000-0003-4970-1265
Emilio CasanovaDepartment of Physiology, Center of Physiology and Pharmacology and Comprehensive Cancer Center (CCC), Medical University of Vienna, AT-1090 Vienna, Austria. emilio.casanova@meduniwien.ac.at.ORCID 0000-0001-7992-5361
Ludwig Boltzmann Institute for Cancer Research · ATComprehensive Cancer Center Vienna · ATSemmelweis University · HUSpanish National Cancer Research Centre · ESAustrian Academy of Sciences · ATMedical University of Graz · ATMedical University of Vienna · ATUniversity of Veterinary Medicine Vienna · AT
Funding
Austrian Science Fund FWF P 25599
Abstract
On the basis of clinical trials using first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), it became a doctrine that V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (
Indexed as
Adenocarcinoma of LungAfatinibCarcinogenesisCell Line, TumorCell ProliferationDrug Resistance, NeoplasmErbB ReceptorsErlotinib HydrochlorideGefitinibHumansLung NeoplasmsMutationProto-Oncogene Proteins p21(ras)Signal TransductionAfatinibEGFR protein, humanErbB ReceptorsErlotinib HydrochlorideGefitinibKRAS protein, humanProto-Oncogene Proteins p21(ras)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.